CRANBURY, N.J., June 28, 2021 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN) a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced the...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]leadership-team-301320529.html